Rx Firms Still Bear Promotional Compliance Burden If Social Media Platform Changes, FDA Says
This article was originally published in The Pink Sheet Daily
Agency’s advertising office Director Tom Abrams offers hints of FDA’s thinking ahead of the infamously delayed social media guidance.
You may also be interested in...
Using social media as a marketing tool should be about building a community and not necessarily focused on brand marketing, Zoetis’ digital strategy manager tells conference attendees.
Company thought sponsored messages on AP’s feed were unbranded, but realized drug name showed up in expanded tweet. Did intricacies of the platform produce an inadvertent violation?
FDA official Tom Abrams recently acknowledged heightened stakeholder interest in guidance on appropriate communications of health care economic data under FDAMA Sec. 114.